Navigation Links
Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Date:11/20/2007

SOUTH SAN FRANCISCO, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 9:00 p.m. PT / 12:00 a.m. ET on January 4, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 21270665.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...New York investment bank KTA Capital,s client Neur...6.7 mil convertible note private placement with a ... was arranged by KTA Capital as Neuren,s exclusive... New York (PRWEB) November 23, 2009 -- The i...LC ("KTA Capital") has announced that it...
(Date:11/24/2009)... 24 Sigma-Aldrich Corpor...ASDAQ OMX conference on Tuesday, December 1st at 1...arties may listen via live audio broadcast over th... m a a ldrich.com/ . Users can click the "Web...gma-Aldrich: Sigma-Aldrich is a leading Life Sci...
(Date:11/24/2009)...if., Nov. 24 NeurogesX, ... focused on developing and commercializing novel p...hony DiTonno, President and Chief Executive Office...r Jaffray Health Care Conference, to be held Decem...York, New York. ,, Mr. DiTonno and Stephen Ghi...
(Date:11/24/2009)...cacy endpoint has been met for patients with advan..., QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - ...the "Company"), a global biopharmaceutical company...announced positive efficacy data from a Phase 2 st... AEZS-108 (formerly AN-152), in patients with adva...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...ektar Therapeutics,(Nasdaq: NKTR ) announced tod...,Directors effective January 23, 2009. Mr. Lerner...een a member of the Nektar Board of Directors,sinc... The Board of Directors and the Company wish t...s made by providing the benefit of his,extensive i...
...9 ThermoGenesis,Corp. (Nasdaq: KOOL ), a leadin... store adult stem cells, announced today it will r...ter ended December 31, 2008, on Wednesday, Februar...cast , Management will host a conference call ...00 PM Eastern) to review the fiscal second quarter...
...f Kingdee enterprise accounting system across its ...., Jan. 29 AMDL, Inc. (NYSE Alternext US: ADL), a... operations in China and the US, announced today i...enterprise accounting system across its US and Chi...sed Kingdee International Software, the new accoun...
Other Biology Technology:ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009 2AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 2AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 3AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 4
(Date:11/26/2009)..., Heidelberg, 27 November 2009 What are the ba...ts required to produce a cell that can survive on ...a cell, and understand how an entire organism func...tions that scientists in a partnership between the...eidelberg, Germany, and the Centre de Regulacio Ge...
(Date:11/25/2009)... Athens, Ga. Bacteria don,t have easy lives. In a...he bugs, they have natural enemies called bacterio...th every two days. , Still, bacteria and anothe...scovered in extreme environments such as deep-sea ...rt because they have a built-in defense system tha...
(Date:11/25/2009)... Over the course of a lifetime, the heart pumps so...n the order to do this, the muscle fibers of the h...oup headed by Dr. Wolfgang Rottbauer, vice chair o...versity Hospital (Chairman: Prof. Dr. H. A. Katus)... the stability of the smallest muscular unit, the ...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3New genetic cause of cardiac failure discovered 2CCMC Celebrates Case Management Week 28Oct 11 17 29 With Second Annual Patricia McCollom Scholarship 58859 1CCMC Celebrates Case Management Week 28Oct 11 17 29 With Second Annual Patricia McCollom Scholarship 58859 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 1Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 4Lincare Holdings Inc Extends Terms of Employment Agreements with Executive Officers 5219 1Lincare Holdings Inc Extends Terms of Employment Agreements with Executive Officers 5219 2
...quences from tiny green algae have provided new in...kton evolve—and further highlights their critical ...ese findings, by a group led by the DOE Joint Geno... Oceanography, University of California, San Diego...e published this week in the Proceedings of the Na...
... potentially assist cancer diagnosis, a new optica...ional images of blood vessels by taking advantage ...s of hemoglobin, the red-blood-cell molecule that ...earch will be presented in Baltimore at CLEO/QELS,...loped at Duke University, should provide 3-D image...
... Institute for Biological Studies have identified ...in healthy muscle and restores normal muscle funct...es. The study, published online in Nature Medicine...ys in a cascade of events triggered by exercise-in...cular pathway, a molecular switch turns on a set o...
Other Biology News:Puzzling plankton yield secrets to role in evolution/global photosynthesis 2Puzzling plankton yield secrets to role in evolution/global photosynthesis 3Catching cancer's spread by watching hemoglobin 2Catching cancer's spread by watching hemoglobin 3Salk scientists hammer out a pathway that promotes muscle cell survival in mice 2
Propidium Iodide Buffer from BioLegend
Mouse Anti-Escherichia coli Lac1 Monoclonal Antibody, Unconjugated, Clone 0.T.81 from Abcam
Goat Anti-Human HADHB Polyclonal Antibody, Unconjugated from IMGENEX
EDG-6 Lysate from Exalpha Biologicals, Inc.
Biology Products: